CD4+ T cells are now known to differentiate into additional effector T-cell subsets (i.e., Th17, Th9, follicular helper T, Th22) with contrasting and unclear roles in the development of CRC (12–14) as well as immunosuppressive cells, like exhausted, anergic/tolerant, and subsets of regulatory T cells (Tregs) that can favor cancer progression (15–18). This evidence concerns the gene CD4 and cancer.